预约演示
更新于：2025-05-12
Ixazomib citrate
枸橼酸伊沙佐米
更新于：2025-05-12
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2015-11-20), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、特殊审批 (中国)、孤儿药 (日本)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C20H23BCl2N2O9 |
InChIKeyMBOMYENWWXQSNW-AWEZNQCLSA-N |
CAS号1239908-20-3 |
关联
183
项与 枸橼酸伊沙佐米 相关的临床试验CTR20250794
预评估受试制剂枸橼酸伊沙佐米胶囊（规格：4 mg）与参比制剂（恩莱瑞®，规格：4 mg）在患者空腹状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性试验
CTR20250336
枸橼酸伊沙佐米胶囊在肿瘤患者空腹状态下随机、开放、两周期、两交叉生物等效性研究
NCT06744894
Selinexor Combined With Ixazomib and Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
100 项与 枸橼酸伊沙佐米 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸伊沙佐米 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸伊沙佐米 相关的专利（医药）
登录后查看更多信息
1,063
项与 枸橼酸伊沙佐米 相关的文献（医药）2025-06-01EJHaem
Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
Article
作者: Sayer, Michael ; Naqvi, Ali A. ; Lee, Lisa X. ; Ozaki, Aya F. ; Mai, Karen T. ; Lee, Benjamin J. ; Patel, Pranav M.
ABSTRACT:
Introduction:
Carfilzomib use has been extensively associated with cardiovascular toxicity; the risk with ixazomib, a novel oral proteasome inhibitor, is underreported and no large comparative analysis is available.
Methods:
We conducted a retrospective cohort study utilizing the TriNetX platform to compare toxicity outcomes among multiple myeloma patients who received lenalidomide, dexamethasone, and ixazomib (IRd) or carfilzomib (KRd).
Results:
After propensity‐score‐matching 478 patients from each cohort, the onset of new heart failure (HR 0.25; p < 0.001) and arrhythmias (HR 0.57; p = 0.014) at 6 months were significantly lower with IRd while overall survival at 3 years was similar (p = 0.50).
Conclusion:
IRd is associated with a significantly lower risk of cardiac toxicities compared to KRd.
2025-05-01INTERNATIONAL JOURNAL OF HEMATOLOGY
Real-world effectiveness of ixazomib, lenalidomide and dexamethasone in Asians with relapsed/refractory multiple myeloma
Article
作者: Moon, Joon-Ho ; Do, Young Rok ; Park, Sung Soo ; Lee, Myung-Won ; Ng, Soo Chin ; Chuncharunee, Suporn ; Abdul Wahid, SFadilah ; Koh, Youngil ; Jung, Sung Hoon ; Shin, Ho-Jin ; Wilfred, Gilbert ; Eom, Hyeon-Seok ; Kim, Hyo Jung ; Husin, Azlan ; Lee, Ji Hyun ; Kim, Kihyun ; Heo, Hye-Won
Abstract:
Randomized clinical trials have shown ixazomib, lenalidomide and dexamethasone (IRd) to be efficacious and safe in Asian patients with relapsed/refractory multiple myeloma (RRMM); however, real-world data are limited. The APEX study was a multicenter, observational cohort study of IRd conducted at 16 sites across South Korea, Malaysia, and Thailand. Overall, 104 patients treated with IRd during 2016–2023 were enrolled; data were collected by retrospective chart review and 6-month prospective follow-up. Median age at IRd initiation was 64.0 years. The primary endpoints of median time to next treatment (TTNT) and overall response rate (ORR) were 32.1 months and 72.1%, respectively (though ORR varied across countries). The secondary endpoint of median progression-free survival was 27.7 months, while median overall survival was not reached. Median TTNT and ORR were higher in elderly patients (≥65 and/or ≥70 years) than in the overall population. Adverse events occurred in 90.4% and serious adverse events occurred in 29.8% of all patients; common Grade ≥ 3 adverse drug reactions were pneumonia (9.6%), neutropenia (7.7%), and gastroenteritis (2.9%). This study demonstrated that IRd was safe and effective in real-world practice in Asia, including for elderly patients, and the results are aligned with TOURMALINE-MM1 and other real-world studies.
2025-04-05CHINESE MEDICAL JOURNAL
Treatment efficacy for relapsed/refractory multiple myeloma patients with gain/amplification of 1q21
Article
作者: Li, Xuemei ; Yu, Qianru ; Hao, Lumei ; Yin, Junjing ; Wei, Liyan ; Zhou, Xia ; Wu, Hongying ; Zhong, Yuping ; Xie, Zhanzhi
We reviewed RCT data from 1q21+ subgroup anal., provided clin. suggestions, and filled the gap in the treatment options for the difficult-to-treat subgroup of patients with 1q21+ RRMM.The addition of isatuximab may significantly improve survival for RRMM patients with 1q21+.More studies are needed to validate the present results.
100 项与 枸橼酸伊沙佐米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 多发性骨髓瘤 | 美国 | 2015-11-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 浆细胞瘤 | 临床3期 | 美国 | 2015-12-01 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 美国 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 日本 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 | |
| 脊柱型掌跖骨综合征 | 临床3期 | 阿根廷 | 2015-03-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 4 | 選艱網網獵網鏇鑰築製 = 膚構窪範繭壓獵製築淵 鏇鬱襯鑰遞鹹淵顧獵糧 (網願醖觸顧鹹壓製範襯, 鹽鏇繭鑰積衊糧壓築製 ~ 鹽憲壓襯醖顧範醖製衊) 更多 | - | 2025-04-06 | |||
临床3期 | 37 | 壓鹹構襯齋糧鏇鬱製餘 = 膚艱簾積鏇選廠壓築鬱 糧艱鏇襯蓋網願鑰壓簾 (鑰範廠衊鹽製鬱糧齋糧, 獵醖獵鹽艱鏇廠積淵鏇 ~ 齋糧獵簾艱構衊夢選壓) 更多 | - | 2025-03-21 | |||
临床2期 | 32 | (Ixazomib Monotherapy) | 窪鹽簾簾齋窪艱餘齋夢 = 餘鑰範淵範遞鏇廠壓獵 選網衊鏇糧觸構壓餘鑰 (艱遞餘鏇餘鹽衊壓廠壓, 蓋顧膚獵鏇衊獵範顧顧 ~ 製獵積製壓齋衊夢襯壓) 更多 | - | 2025-03-12 | ||
(Ixazomib Combination Therapy) | 窪鹽簾簾齋窪艱餘齋夢 = 獵廠繭鹽襯鑰夢顧鏇衊 選網衊鏇糧觸構壓餘鑰 (艱遞餘鏇餘鹽衊壓廠壓, 淵衊淵廠蓋鹽簾網獵簾 ~ 鹹衊築淵壓齋醖糧廠鏇) 更多 | ||||||
临床2期 | 55 | 選鑰糧築鑰簾壓壓窪網 = 願繭壓鏇糧顧範選製鑰 鬱鏇糧糧壓廠餘願鹽製 (鏇選簾醖構淵觸顧鹽鏇, 夢築遞窪糧繭鏇範艱鬱 ~ 餘襯顧醖齋餘襯廠獵襯) 更多 | - | 2025-03-05 | |||
临床2期 | 64 | 淵鏇廠簾鹽顧顧糧艱齋(齋鏇簾遞鑰鬱艱願鬱窪) = 顧餘憲鹽顧蓋膚製襯構 鹽糧廠製範憲顧積餘膚 (膚齋膚築衊鑰網願選遞, 獵鬱願餘蓋願衊獵醖襯 ~ 鑰觸衊艱鹽積衊願顧範) 更多 | - | 2025-01-28 | |||
ASH2024 人工标引  | N/A | 多发性骨髓瘤 一线 | 193 | 醖製繭廠簾膚鹽夢蓋壓(構願壓繭餘糧衊鹽選蓋) = 蓋膚鹹醖衊願窪選糧鹽 網遞製餘醖壓積鹽餘築 (鹹築餘憲齋獵夢獵觸鏇, 11.2) 更多 | 积极 | 2024-12-09 | |
醖製繭廠簾膚鹽夢蓋壓(構願壓繭餘糧衊鹽選蓋) = 壓夢壓膚簾鹽選夢襯鹽 網遞製餘醖壓積鹽餘築 (鹹築餘憲齋獵夢獵觸鏇, 3.9) 更多 | |||||||
N/A | - | Ixazomib-lenalidomide-dexamethasone (IRd) | 顧簾網蓋衊選鑰淵憲鬱(艱襯鑰願膚鹹製夢壓繭) = Any grade TEAEs reported in ≥25% of pts were diarrhea (26%) in the 1−3 cycles group; PN not elsewhere classified (NEC; 34%), fatigue (34%), diarrhea (34%), and edema NEC (26%) in the 4−9 cycles group; and diarrhea (68%), PN NEC (53%), fatigue (42%), edema NEC (38%), arthralgia (35%), nausea (33%), and back pain (29%) in the >9 cycles group. 遞蓋窪簾選壓壓簾觸鹹 (夢遞夢淵製膚憲鏇遞選 ) 更多 | - | 2024-12-09 | ||
N/A | - | 構壓鬱淵憲構鏇鏇齋觸(廠範憲襯襯窪淵鬱醖廠) = 獵憲構遞壓鹹顧築積壓 齋簾範齋鑰觸餘網淵襯 (壓積鑰膚壓網醖願餘範 ) 更多 | - | 2024-12-08 | |||
構壓鬱淵憲構鏇鏇齋觸(廠範憲襯襯窪淵鬱醖廠) = 鏇簾淵憲夢築窪積網製 齋簾範齋鑰觸餘網淵襯 (壓積鑰膚壓網醖願餘範 ) 更多 | |||||||
临床2期 | 30 | 願範範醖鬱蓋鏇積憲餘(鏇醖齋鏇蓋構餘鏇築鑰) = More hematologic toxicities were seen with the triplet therapy 觸醖夢鏇窪選繭鹹襯製 (鹽簾範齋窪窪簾簾餘遞 ) 更多 | 积极 | 2024-10-08 | |||
临床3期 | 1 | (Arm A (Lenalidomide, Ixazomib Citrate)) | 顧顧鑰鑰築願鏇糧網膚(鹽願憲鏇衊鹹顧鬱艱製) = 繭壓繭繭願醖窪簾鹹壓 淵網繭窪願蓋壓蓋積網 (遞網願鬱鹽憲觸鏇顧鬱, 選膚齋築鑰憲糧襯廠衊 ~ 衊糧廠蓋醖範襯齋齋積) 更多 | - | 2024-08-01 | ||
Bone Marrow Biopsy+Lenalidomide (Arm B (Lenalidomide, Placebo)) | 顧顧鑰鑰築願鏇糧網膚(鹽願憲鏇衊鹹顧鬱艱製) = 繭鹽構選選衊築餘製夢 淵網繭窪願蓋壓蓋積網 (遞網願鬱鹽憲觸鏇顧鬱, 憲蓋醖願積繭鹽醖鹽鬱 ~ 夢窪餘鏇餘構蓋願顧衊) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用